These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 34296055)

  • 1. Tumor Response End Points as Surrogates for Overall Survival in Immune Checkpoint Inhibitor Trials: A Systematic Review and Meta-Analysis.
    Kok PS; Yoon WH; Lord S; Marschner I; Friedlander M; Lee CK
    JCO Precis Oncol; 2021 Jul; 5():. PubMed ID: 34296055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of Progression-Free Survival Rate at 6 Months and Objective Response for Estimating Overall Survival in Immune Checkpoint Inhibitor Trials: A Systematic Review and Meta-analysis.
    Kok PS; Cho D; Yoon WH; Ritchie G; Marschner I; Lord S; Friedlander M; Simes J; Lee CK
    JAMA Netw Open; 2020 Sep; 3(9):e2011809. PubMed ID: 32897371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Defining the Most Appropriate Primary End Point in Phase 2 Trials of Immune Checkpoint Inhibitors for Advanced Solid Cancers: A Systematic Review and Meta-analysis.
    Ritchie G; Gasper H; Man J; Lord S; Marschner I; Friedlander M; Lee CK
    JAMA Oncol; 2018 Apr; 4(4):522-528. PubMed ID: 29470579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of high PD-L1 expression on the surrogate endpoints and clinical outcomes of anti-PD-1/PD-L1 antibodies in non-small cell lung cancer.
    Ito K; Miura S; Sakaguchi T; Murotani K; Horita N; Akamatsu H; Uemura K; Morita S; Yamamoto N
    Lung Cancer; 2019 Feb; 128():113-119. PubMed ID: 30642442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Milestone Analyses of Immune Checkpoint Inhibitors, Targeted Therapy, and Conventional Therapy in Metastatic Non-Small Cell Lung Cancer Trials: A Meta-analysis.
    Blumenthal GM; Zhang L; Zhang H; Kazandjian D; Khozin S; Tang S; Goldberg K; Sridhara R; Keegan P; Pazdur R
    JAMA Oncol; 2017 Aug; 3(8):e171029. PubMed ID: 28617920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune-related adverse events as potential surrogates of immune checkpoint inhibitors' efficacy: a systematic review and meta-analysis of randomized studies.
    Amoroso V; Gallo F; Alberti A; Paloschi D; Ferrari Bravo W; Esposito A; Cosentini D; Grisanti S; Pedersini R; Petrelli F; Berruti A
    ESMO Open; 2023 Apr; 8(2):100787. PubMed ID: 36842300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of Milestone Restricted Mean Survival Time Ratio With Overall Survival Hazard Ratio in Randomized Clinical Trials of Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.
    Wang ZX; Wu HX; Xie L; Wang YN; Yang LP; He MM; Luo HY; Ding PR; Xie D; Chen G; Li YH; Wang F; Xu RH
    JAMA Netw Open; 2019 May; 2(5):e193433. PubMed ID: 31050784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive evaluation of surrogate endpoints to predict overall survival in trials with PD1/PD-L1 immune checkpoint inhibitors plus chemotherapy.
    Villacampa G; Cresta Morgado P; Navarro V; Viaplana C; Dienstmann R
    Cancer Treat Rev; 2023 May; 116():102542. PubMed ID: 37003083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative efficacy of chemoimmunotherapy versus immunotherapy for advanced non-small cell lung cancer: A network meta-analysis of randomized trials.
    Pathak R; De Lima Lopes G; Yu H; Aryal MR; Ji W; Frumento KS; Wallis CJD; Klaassen Z; Park HS; Goldberg SB
    Cancer; 2021 Mar; 127(5):709-719. PubMed ID: 33119177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
    Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
    Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complete response associated with immune checkpoint inhibitors in advanced non-small-cell lung cancer: a meta-analysis of nine randomized controlled trials.
    Li J; He Q; Yu X; Khan K; Weng X; Guan M
    Cancer Manag Res; 2019; 11():1623-1629. PubMed ID: 30863172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer.
    Mezquita L; Auclin E; Ferrara R; Charrier M; Remon J; Planchard D; Ponce S; Ares LP; Leroy L; Audigier-Valette C; Felip E; Zerón-Medina J; Garrido P; Brosseau S; Zalcman G; Mazieres J; Caramela C; Lahmar J; Adam J; Chaput N; Soria JC; Besse B
    JAMA Oncol; 2018 Mar; 4(3):351-357. PubMed ID: 29327044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of classical clinical endpoints as surrogates for overall survival in patients treated with immune checkpoint blockers: a systematic review and meta-analysis.
    Kaufman HL; Schwartz LH; William WN; Sznol M; Fahrbach K; Xu Y; Masson E; Vergara-Silva A
    J Cancer Res Clin Oncol; 2018 Nov; 144(11):2245-2261. PubMed ID: 30132118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surrogate endpoints for overall survival in randomized clinical trials testing immune checkpoint inhibitors: a systematic review and meta-analysis.
    Sala I; Pagan E; Pala L; Oriecuia C; Musca M; Specchia C; De Pas T; Cortes J; Giaccone G; Postow M; Gelber RD; Bagnardi V; Conforti F
    Front Immunol; 2024; 15():1340979. PubMed ID: 38348030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship Between Progression-Free Survival, Objective Response Rate, and Overall Survival in Clinical Trials of PD-1/PD-L1 Immune Checkpoint Blockade: A Meta-Analysis.
    Ye J; Ji X; Dennis PA; Abdullah H; Mukhopadhyay P
    Clin Pharmacol Ther; 2020 Dec; 108(6):1274-1288. PubMed ID: 32564368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index.
    Buti S; Bersanelli M; Perrone F; Tiseo M; Tucci M; Adamo V; Stucci LS; Russo A; Tanda ET; Spagnolo F; Rastelli F; Pergolesi F; Santini D; Russano M; Anesi C; Giusti R; Filetti M; Marchetti P; Botticelli A; Gelibter A; Occhipinti MA; Ferrari M; Vitale MG; Nicolardi L; Chiari R; Rijavec E; Nigro O; Tuzi A; De Tursi M; Di Marino P; Conforti F; Queirolo P; Bracarda S; Macrini S; Gori S; Zoratto F; Veltri E; Di Cocco B; Mallardo D; Vitale MG; Santoni M; Patruno L; Porzio G; Ficorella C; Pinato DJ; Ascierto PA; Cortellini A
    Eur J Cancer; 2021 Jan; 142():18-28. PubMed ID: 33212418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlations between objective response rate and survival-based endpoints in first-line advanced non-small cell lung Cancer: A systematic review and meta-analysis.
    Goring S; Varol N; Waser N; Popoff E; Lozano-Ortega G; Lee A; Yuan Y; Eccles L; Tran P; Penrod JR
    Lung Cancer; 2022 Aug; 170():122-132. PubMed ID: 35767923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of treatment timing and sequence of immune checkpoint inhibitors and anti-angiogenic agents for advanced non-small cell lung cancer: A systematic review and meta-analysis.
    Matsumoto K; Shiroyama T; Kuge T; Miyake K; Yamamoto Y; Yoneda M; Yamamoto M; Naito Y; Suga Y; Fukushima K; Koyama S; Iwahori K; Hirata H; Nagatomo I; Takeda Y; Kumanogoh A
    Lung Cancer; 2021 Dec; 162():175-184. PubMed ID: 34823108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of cyclo-oxygenase inhibitor use during checkpoint blockade immunotherapy in patients with metastatic melanoma and non-small cell lung cancer.
    Wang SJ; Khullar K; Kim S; Yegya-Raman N; Malhotra J; Groisberg R; Crayton SH; Silk AW; Nosher JL; Gentile MA; Mehnert JM; Jabbour SK
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33020239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progression-free survival assessed per immune-related or conventional response criteria, which is the better surrogate endpoint for overall survival in trials of immune-checkpoint inhibitors in lung cancer: A systematic review and meta-analysis.
    Zhu GL; Yang KB; Tang SQ; Peng L
    Cancer Med; 2021 Dec; 10(23):8272-8287. PubMed ID: 34668660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.